Compare Payoneer Global Inc (PAYO) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Payoneer Global Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Payoneer Global Inc trades at $7.16 (market cap $2.43B), while Vertex Pharmaceuticals Incorporated trades at $508.92 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 52.5× Payoneer Global Inc's market cap, and Payoneer Global Inc is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Payoneer Global Inc for 61 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| PAYO | VRTX | |
|---|---|---|
Market Cap | $2.43B | $127.55B |
Volume | 1,342,701 | 1,487,944 |
Sector | Technology | Health |
52-Week High | $7.18 | $557.96 |
52-Week Low | $4.27 | $407.37 |
Typical Hold Time | 61 Days | 120 Days |
Enterprise Value | $2.17B | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Payoneer Global (PAYO) trades at $7.16, showing minimal daily movement with a 0.14% gain. The stock maintains a bullish technical signal with strong moving average support, though oscillators remain neutral. Fundamentally, revenue grew to $821 million in 2025 with a 78% gross margin, but net income declined to $73 million. Recent news highlights the company's acquisition agreement with Nuvei and strategic expansion into India, while earnings show mixed quarterly performance with two misses and one beat in the last four quarters.
PAYO presents a mixed outlook with 60% analyst buy ratings supporting growth potential from international expansion and partnership renewals. However, declining profit margins, elevated P/E ratio of 51.18, and acquisition-related uncertainties pose significant risks. The stock's current technical strength contrasts with fundamental challenges, requiring careful monitoring of execution against growth initiatives.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
